Co-led Pinnacle Medicines' oversubscribed $89M Series B alongside LAV to advance its oral peptide therapeutics pipeline.
Pinnacle Medicines is a biotechnology company that develops oral peptide therapeutics designed to deliver biologic-level efficacy with the convenience of oral dosing for immunology and cardiometabolic diseases
Pinnacle Medicines is a biotechnology company that develops oral peptide therapeutics designed to deliver biologic-level efficacy with the convenience of oral dosing for immunology and cardiometabolic diseases.